We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-19.00 | -1.07% | 1,756.00 | 1,753.00 | 1,754.00 | 1,770.00 | 1,740.00 | 1,770.00 | 8,298,343 | 16:35:18 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 14.65 | 72.19B |
Date | Subject | Author | Discuss |
---|---|---|---|
20/1/2017 09:35 | This shouldn't follow the price of sterling it's well under valued at this price | mj19 | |
19/1/2017 09:53 | 19th jan Deutsche hold tp 1800p 19th jan Liberum buy tp 1900p | philanderer | |
19/1/2017 09:22 | IN at 1562.25 (with dividend cash) ..... ;0) | tradermichael | |
17/1/2017 14:25 | Post May speech.. "The pound's on course for its biggest one-day rise against the dollar since 2008" | philanderer | |
16/1/2017 18:42 | 'Why Trump Faces Stiff Fight to Slash Drug Prices' | philanderer | |
16/1/2017 10:28 | 16th jan Jefferies buy tp 1750p up from 1700p | philanderer | |
16/1/2017 09:30 | Well with the £ @ 12000 against the US$ this is becoming a mouthwatering takeover target imho Trump rally will fade and more cash will pour into these multi national, strong management,blue chip plays with a decent divi. | ny boy | |
15/1/2017 15:53 | Dr B, I think you will find Farage has more than considerable minority support. The forthcoming by election results should be quite interesting even if Farage is no longer leader. In the meantime I continue to hold as the dividend income is remarkable. I'm sure GSK will weather the Trump storm. | chessman2 | |
15/1/2017 09:24 | Trump will shake everything up ! However to every action there is an equal and opposite reaction. The real question is how other nations to react to the changes Trump will bring. Particular China on trade and Europe on funding. NATO. | atlantic57 | |
15/1/2017 09:10 | Hard to argue against some sort of action against high drug prices. Unfortunately big pharma hasn't covered itself in glory with multiple fines for misconduct. But somehow the price of development also needs to drop to keep the incentive for new drugs. | dr biotech | |
12/1/2017 19:36 | Trump likely to target drug prices (FT). | alphorn | |
12/1/2017 19:13 | Nope. Don't think so | deanowls | |
12/1/2017 12:31 | Will there is a special dividend this year ?? | robrah | |
12/1/2017 12:26 | GSK is viewed as a strategic asset, HMG would be unlikely to allow a sale in its current form imv. | essentialinvestor | |
12/1/2017 00:52 | In the NYSE the share price had recovered most of the drop we saw here by the market close. | woodhawk | |
12/1/2017 00:17 | Trump is a fool, what press conference, a complete shambles, one has to be worried but if these get cheaper I will add more, a takeover from overseas will be even more likely, whilst £ is in a rocky place. | ny boy | |
11/1/2017 20:55 | DT is rattling the cages of various industries, auto, pharma etc. He could, of course turn his attention to all the Delaware company shelters - but then he may have some there too! | alphorn | |
11/1/2017 20:51 | It is difficult to ascertain what affect Trump will have on pharmaceutical companies but I am convinced it is going to be nothing matching his rhetoric. Even with a republican majority there will be strong support for pharmaceutical companies within the party and legislation moving forward will need agreement with the democrats because significantly more(%) than a majority vote is needed to pass some legislation through. Obamacare introduces millions into the healthcare services umbrella and democrats will want to see this remains the case. Additionally, use of hospital beds is extremely expensive and if they want to reduce - probably one of the greatest single costs to hospitals - then choosing the best drug for efficacy most likely saves the most; this leads to not much choice of suppliers where bidding then becomes pointless or impossible. If you want the drug - the sad fact is - you are going to have to pay for it. If you want more choice you need to encourage investment which, in turn, is only attracted if pharma can make money. The buffoon hasn't really thought this one out just like arresting Hillary or building the Mexican fence. | minerve | |
11/1/2017 20:49 | Moving manufacture is a bit of a nonsense; much of the high value (margin) actives will be produced in low tax areas. Pharma manufacture takes a long time to set up with all the approvals - not like producing a pair of socks. DT will have to hit pricing or taxes to achieve anything in the short term. | alphorn | |
11/1/2017 20:49 | By no means a sector meltdown atm, PFE and NVS down under 2%. Would expect some continued volatility. | essentialinvestor | |
11/1/2017 20:27 | Back up to 1602p stateside now. | philanderer | |
11/1/2017 18:59 | Pretty rich bozo. | philo124 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions